Allos Therapeutics to Present at the UBS Global Life Sciences Conference
22 Setembro 2005 - 10:00AM
PR Newswire (US)
WESTMINSTER, Colo., Sept. 22 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that the Company
will participate in the UBS 2005 Global Life Sciences Conference,
to be held September 26th - 29th in New York City. Michael E. Hart,
the Company's President and Chief Executive Officer, will give a
30-minute corporate overview on Thursday, September 29th at 9:30 AM
ET. The presentation will be webcast live and may be accessed by
visiting the Allos website at http://www.allos.com/. A replay of
the webcast will also be available on the Company's website until
Saturday, October 29, 2005. About Allos Therapeutics, Inc. Allos
Therapeutics, Inc. (NASDAQ:ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. Our lead product
candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small
molecule designed to sensitize hypoxic, or oxygen-deprived, tumor
tissue during radiation therapy. EFAPROXYN is currently being
evaluated as an adjunct to whole brain radiation therapy in a
pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. Our other product candidates are: PDX
(pralatrexate), a small molecule chemotherapeutic agent (DHFR
inhibitor) currently under investigation as both a single agent and
in combination therapy regimens in patients with non-small cell
lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule
chemotherapeutic agent bioactivated by the enzyme DT-diaphorase
currently under evaluation in patients with advanced solid tumors.
For more information, please visit the Company's web site at:
http://www.allos.com/. Safe Harbor Statement The anticipated
presentation will contain forward-looking statements that involve
significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the
"Risk Factors" section of the Company's Form 10-K for the year
ended December 31, 2004 and in the Company's periodic reports on
Form 10-Q and Form 8-K. The Company does not undertake any
obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer
Neiman, Manager, Corporate Communications, of Allos Therapeutics,
+1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics (MM)